SL327 is a MEK inhibitor. SL327 blocks acquisition but not expression of lithium-induced conditioned place aversion: a behavioral and immunohistochemical study. SL327 had no affect on acquisition, expression, or extinction of EtOH-induced CPP in mice despite causing significant reduction of pERK levels in multiple brain regions. Additionally, although SL327 caused a generalized depression of locomotor activity, it did not prevent the development of EtOH-sensitization.
MEK Inhibitor Related Products:
Selumetinib; Mirdametinib (PD0325901); Trametinib; PD184352 (CI-1040); PD98059; BIX02189; U0126-EtOH; Pimasertib; BIX02188; TAK-733; Binimetinib (MEK162); Refametinib; GDC-0623; RO5126766 (CH5126766); Cobimetinib; APS-2-79 hydrochloride; AZD8330